

Technology Appraisal Committee B Interests Register

Topic: ID6480 Dupilumab for treating severe chronic rhinosinusitis with nasal polyposis (Review of TA648)

Publication Date: 11 September 2025

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
David McAllister	TAC Member	Non-financial – Professional	In David's academic work he uses trials provided by Sanofi via the Vivli trial sharing platform	11/06/2025	It was agreed that David's declaration would not prevent him from participating in discussions on this appraisal.
Claire Hopkins	Clinical Expert	Direct Financial	<p>Speakers fees Oct 2024 Masterclass in Use of biologics in CRSwNP – Brazilian National ENT Congress – Sanofi - £1950</p> <p>Consultancy Fees Oct 2024 – Sanofi £960</p> <p>Consultancy fees June 2024 – Sanofi £1980</p> <p>International Medical Advisory Board June 2024 Sanofi £2649</p> <p>Speakers fees April 2024 Masterclass in Use of biologics in</p>	02/07/2025	It was agreed that Ms Hopkins' declaration would not prevent her from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>CRSwNP – endoKL Congress – Sanofi - £1650</p> <p>Speakers fees May 2023 Type 2 inflammation summit, Singapore, repeated KualaLumpur- Sanofi £5852</p> <p>Speakers fees March 2022 Dubai Masterclass – Sanofi - £4836</p> <p>Speakers fees – Sept 2021 European Rhinological Society Symposium - £1820</p>		
Carl Philpot	Clinical Expert	Direct Financial	<p>Agreed to payment for consultancy for Sanofi</p> <p>Nominated by Fifth Sense</p> <p>Fifth Sense has received no funding from Sanofi in the last 12 months other than the expense reimbursement detailed below. Since early 2024 Fifth Sense has been part of a series of roundtable discussions, alongside a number of other patient-facing organisations, around patient access to medicines</p>	02/07/2025	It was agreed that Mr Philpot's declaration would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			with multiple indications. These roundtables have been organised by Sanofi, and the company covered the costs of CEO Duncan Boak's rail fare, £80, for the first meeting held in-person in London.		
Andrew Knell	Patient Expert	In-direct - Financial	<p>Sanofi UK engaged Sinus UK CIC in a paid consultancy to organise patient roundtables to gain a better understanding of the impact of living with nasal polyps</p> <p>Managing Director of Opus Communications limited, a health communication agency which works with pharmaceutical companies (but no one in the CRS space and not with Sanofi UK)</p> <p>In the last 12 months Mr Knell has undertaken work as a patient advocate with Sanofi UK and Sanofi Regeneron, providing the patient perspective on living with CRSwNP</p>	02/07/2025	It was agreed that Mr Knell's declaration would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Sophie Dodworth	Patient Expert	In-direct Financial	Fifth Sense has received no funding from Sanofi in the last 12 months other than the expense reimbursement detailed below. Since early 2024 Fifth Sense has been part of a series of roundtable discussions, alongside a number of other patient-facing organisations, around patient access to medicines with multiple indications. These roundtables have been organised by Sanofi, and the company covered the costs of CEO Duncan Boak's rail fare, £80, for the first meeting held in-person in London.	02/07/2025	It was agreed that Ms Dodworth's declaration would not prevent him from providing expert advice to the committee.